

SUPPLEMENT APPROVAL
March 21, 2019

Bio-Rad Medical Diagnostics GmbH
Attention: Dr. Rolf Vornhagen
Industriestrasse 1
D-63303 Dreieich
Germany

Dear Dr. Vornhagen:

We have approved your requests submitted October 10, 2018, received October 11, 2018, to supplement your Biologics License Applications (BLA) submitted under section 351(a) of the Public Health Service Act (42 U.S.C. 262) to extend the intended use of the following products for processing on the automated IH-500 analyzer:

STN Name of Biological Products

BL 125094/145*	Blood Grouping Reagent, Anti-A (Murine Monoclonal) (Formulated for Automated Testing)
BL 125096/87	Blood Grouping Reagent, Anti-A,B (Murine Monoclonal) (Formulated for Automated Testing)
BL 125097/95	Blood Grouping Reagent, Anti-D (Monoclonal) (IgM) (Formulated for Automated Testing)
BL 125202/77	Blood Grouping Reagent, Anti-E (Monoclonal) (Formulated for Automated Testing)
BL 125203/75	Blood Grouping Reagent, Anti-e (Monoclonal) (Formulated for Automated Testing)
BL 125204/74	Blood Grouping Reagent, Anti-K (Monoclonal) (Formulated for Automated Testing)
BL 125205/73	Blood Grouping Reagent, Anti-c (Monoclonal) (Formulated for Automated Testing)
BL 125206/75	Blood Grouping Reagent, Anti-C (Monoclonal) (Formulated for Automated Testing)

We hereby approve the draft package insert labeling submitted in amendment 2, dated March 18, 2019. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website, <http://www.fda.gov/udi>.

Please submit all final printed labeling as PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

We will include the information contained in the above-referenced supplements in your BLA files.

Sincerely,

Orieji Illoh, MD
Director
Division of Blood Components and Devices
Office of Research and Review
Center for Biologics Evaluation and Research